Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomised, Parallel-group, Active-controlled, Double-blind Study to Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma

NCT02260804 is registered in ClinicalTrials.gov with Celltrion as lead sponsor.

NCT NCT02260804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02260804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomised, Parallel-group, Active-controlled, Double-blind Study to Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma
Lead sponsor
Celltrion
Phase
Phase 3
Overall status
Completed
Start date
November 9, 2015
Completion date
September 4, 2019
Enrollment
258 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma